Business
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product CandidateREHOVOT, Israel, Feb. 26, 2026 /PRNewswire/ --
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product CandidateREHOVOT, Israel, Feb. 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market.The allowed patent application covers a polymerizable solution and its use in tissue augmentation. The composition is injected into a sub-epidermal tissue space and subsequently polymerized in situ using external light activation. This invention underpins CollPlant's proprietary photocuring platform for dermal fillers.\"This patent allowance represents another important milestone in executing our strategy to expand the clinical and commercial applications of our rhCollagen platform into high-value aesthetic markets,\" said Yehiel Tal, Chief Executive Officer of CollPlant. \"South Korea is a strategically important market in aesthetic medicine, and strengthening our intellectual property position in this region further enhances the long-term value of our technology.\"Mr. Tal added, \"Beyond skin lifting, our photocurable rhCollagen-based filler platform was designed to support structural tissue restoration. Upon light activation, the material forms a supportive scaffold intended to enhance long-term contour stability. The technology is designed not only to restore facial contours but also to provide a regenerative matrix that may promote tissue integration and durable structural improvement. With patent protection extending through 2039, we believe this innovation positions us to compete effectively, upon completion of development, in a global injectable soft-tissue filler market currently estimated to exceed $6 billion and continuing to grow.\"The polymerizable formulation comprises chemically modified rhCollagen together with additional constituents, including a hyaluronic acid-based filler component. The solution is engineered to exhibit viscosity suitable for extrusion through a surgical needle of at least 27-gauge at the temperature of use, while enabling post-in...